Canada Pension Plan Investment Board Invests $1.74 Million in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Canada Pension Plan Investment Board acquired 219,200 Xeris Biopharma shares worth approximately $1.74 million, while institutional investors and hedge funds collectively own 42.75% of the company.
• Analyst sentiment is mixed: Barclays raised its price target to $12 and maintained an “overweight” rating, but the overall consensus remains “Hold” with three Buy, two Hold, and one Sell rating.
• Xeris reported quarterly revenue of $92.1 million, exceeding estimates, but its loss of $0.18 per share missed expectations. The stock opened at $8.48, and insiders have sold approximately $1.94 million of shares over the past three months.

Canada Pension Plan Investment Board acquired a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 219,200 shares of the company's stock, valued at approximately $1,736,000. Canada Pension Plan Investment Board owned approximately 0.12% of Xeris Biopharma as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in XERS. Walleye Capital LLC acquired a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $4,841,000. Rice Hall James & Associates LLC purchased a new stake in shares of Xeris Biopharma during the first quarter worth about $1,456,000. Janus Henderson Group PLC raised its position in shares of Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company's stock valued at $1,713,000 after buying an additional 225,602 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Xeris Biopharma in the first quarter valued at approximately $1,204,000. Finally, Sei Investments Co. lifted its stake in shares of Xeris Biopharma by 45.0% during the first quarter. Sei Investments Co. now owns 579,210 shares of the company's stock valued at $3,359,000 after buying an additional 179,863 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on XERS shares. Barclays raised their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Weiss Ratings downgraded Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $12.00.

Xeris Biopharma Price Performance

XERS opened at $8.48 on Monday. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The business has a 50-day moving average of $8.29 and a two-hundred day moving average of $6.93. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -77.09 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million for the quarter, compared to analysts' expectations of $90.12 million. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $97,440.00. Following the completion of the sale, the director directly owned 126,500 shares in the company, valued at $770,385. This represents a 11.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the company's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the sale, the insider owned 1,361,053 shares of the company's stock, valued at approximately $11,568,950.50. The trade was a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 254,832 shares of company stock worth $1,937,915. 4.35% of the stock is owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source